Dr. Nivaggioli served as CEO of Avicena, a company focused on neurodegenerative diseases, such as ALS, Huntington and Parkinson, where she brought all programs from Phase I to III, with grants from NIH of over $80M and additional funding from VCs. These programs were all licensed at Phase III stage to Marathon Pharma.
Dr. Nivaggioli also served as CEO of Peninsula Skincare labs, a dermaceutical company and QuRetino, a pre-clinical stage dermatology company, as well as holding senior level positions at Gillette Corp R&D. She is currently a managing partner at CN Partners, a consulting firm for dermatology companies, where she is focused on launching a new topical lidocaine product for cosmetic dermatologists using a novel transdermal delivery technology.
She holds a BA from Oberlin College and earned her Master’s degree, as well as Ph.D.. in Bioorganic Chemistry from the University of Toronto. She conducted her post-doctorate work at MIT.
Current role